Animal Health Collaborations Rejuvenate Bio has an ongoing collaboration with Merck Animal Health to develop and commercialize canine gene therapies, including a program for canine osteoarthritis. This signals a ready-made path for veterinary CROs, contract manufacturing partners, and outreach to animal-health companies pursuing gene therapy solutions.

Aging Disease Focus The company targets core drivers of chronic age-related diseases in humans and animals through gene expression and epigenetic reprogramming. This positions opportunities for pharma and biotech partners focused on aging, cardiovascular, metabolic, and renal conditions to explore co-development, licensing, or research collaborations.

Growth Readiness With active research momentum and cross-species ambition, Rejuvenate Bio appears poised for strategic investments, licensing deals, or CRO/CMO partnerships to scale preclinical work and early-stage manufacturing as it advances.

Credibility Momentum Origins in the Wyss Institute at Harvard Medical School, along with industry recognition and leadership visibility, provide credibility to engage large pharma, research institutions, and venture sponsors in licensing, collaboration, or co-development discussions.

Strategic Outreach Active participation in conferences, pitches, and media coverage creates multiple entry points for business development—from veterinary health networks to human therapeutics alliances—supporting inbound partnership discussions and strategic licensing opportunities.